Regulatory landscapes evolve with significant developments including the US FDA's ongoing device user fee agreement negotiations, and shifting stances on coverage of anti-obesity GLP-1 drugs by CMS with possible pilot programs under consideration. Meanwhile, high tariff announcements on pharmaceutical imports signal increased trade tensions. Separately, controversies unfold with the FDA’s cancer drug decision processes leading to industry and expert pushbacks and highlighting complex regulatory dynamics.